secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2026-03-18T23:59:59+00:00
Accession:  0001437749-26-008733
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genprex announces positive preclinical data for Reqorsa at AACR 2026
--------------------------------------------------------------------

- TROP2 and PTEN identified as potential biomarkers of primary resistance to TUSC2 gene therapy; 50% of NSCLC cell lines resistant.
- Reqorsa plus alectinib achieved 79% tumor shrinkage in ALK+ sensitive model, 23% improvement vs alectinib alone.
- In alectinib-resistant model, Reqorsa + alectinib produced synergistic tumor reduction and improved overall survival (p=0.0001).
- TUSC2 restoration enhanced NK cell cytotoxicity; 67% of Tusc2 KO mice and 33% of wild-type mice achieved complete tumor regression.
- Findings support progression toward clinical trials for ALK+ NSCLC and biomarker-guided patient selection.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774926008733/0001437749-26-008733-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774926008733/gnpx20260316_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-008733

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer